Aquatic Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Aquatic Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$144K	Sell	455 -4,839	-91%	-$1.14M	﹤0.01%	1050
2026 Q1	$1.06M	Buy	+5,294	New	+$1.05M	0.03%	544
2025 Q4	–	Sell	-6,598	Closed	-$1.17M	–	1598
2025 Q3	$1.17M	Buy	+6,598	New	+$981K	0.02%	616
2025 Q1	–	Sell	-703	Closed	-$75.3K	–	1467
2024 Q4	$75.3K	Sell	703 -197	-22%	-$22.3K	﹤0.01%	1116
2024 Q3	$90.1K	Sell	900 -900	-50%	-$90.6K	﹤0.01%	936
2024 Q2	$152K	Sell	1,800 -3,200	-64%	-$255K	0.01%	816
2024 Q1	$366K	Buy	+5,000	New	+$369K	0.01%	625
2023 Q4	–	Sell	-100	Closed	-$6K	–	1495
2023 Q3	$6K	Buy	+100	New	+$6.58K	﹤0.01%	1158
2023 Q2	–	Sell	-2,700	Closed	-$199K	–	1568
2023 Q1	$199K	Sell	2,700 -9,000	-77%	-$640K	0.01%	585
2022 Q4	$781K	Sell	11,700 -2,406	-17%	-$156K	0.06%	386
2022 Q3	$758K	Buy	+14,106	New	+$829K	0.07%	318
2022 Q1	–	Sell	-802	Closed	-$77K	–	1314
2021 Q4	$77K	Buy	+802	New	+$74.1K	0.15%	180

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aquatic Capital Management's LGND Position: Q2 2026 in Review

Aquatic Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 91% in Q2 2026, selling an estimated $1.14M and leaving 455 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #1050.

Aquatic Capital Management first reported a position in LGND in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.17M in Q3 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Aquatic Capital Management held 455 shares of Ligand Pharmaceuticals worth $144K as of Q2 2026.
Aquatic Capital Management sold 4,839 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.14M.
Ligand Pharmaceuticals made up ﹤0.01% of Aquatic Capital Management's portfolio in Q2 2026, its #1050 holding.
Aquatic Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
Aquatic Capital Management's Ligand Pharmaceuticals position peaked at $1.17M in Q3 2025.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.